Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Codrituzumab||GC-33|RG 7686|RG7686|RG-7686|RO 5137382|RO5137382||Codrituzumab (GC-33) is a monoclonal antibody against Glypican-3 (GPC-3), which may result in cytotoxicity due to its association with CD16/Fc-gamma RIIIa (PMID: 27085251).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||hepatocellular carcinoma||no benefit||Codrituzumab||Phase II||Actionable||In a Phase II trial, previously treated hepatocellular carcinoma patients treated with Codrituzumab did not demonstrate a signficantly greater PFS (2.6 vs 1.5 mo) or OS (8.7 vs 10 mo) when compared to placebo (PMID: 27085251).||27085251|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|